PROMACE-CYTABOM TREATMENT FOR ANGIOCENTRIC IMMUNOPROLIFERATIVE LYMPHOMA

本试验旨在改善患者的长期生存率。与 好的。 这项研究是从美国国立卫生研究院（NCI）的一项观察发展而来的 ”（《说文》）III级AIL（或血管中心性淋巴瘤）， 接受积极联合化疗的患者， 与患者相比，缓解率和生存率提高。一级或二级 用低剂量烷化剂和/或泼尼松治疗AIL。 半年 的PTS。低剂量的慢性治疗最终发展成淋巴瘤 对治疗无效，大多数人最终死于疾病。 因此，pts。最初诊断为显性淋巴瘤的患者 长期生存率高于pts。疾病（一级和二级AIL） 传统上认为是癌前病变或良性炎症状态。 本研究旨在确定是否所有患者。AIL将受益于 初始强化联合化疗。 14分。已被录入 study. 11/14 pts (79%）已达到完全缓解。 3分。 复发（27%）; 3例复发者中有2例接受了ABMT， 持久的第二次缓解。 一次感应失败接受了辐射， 持续缓解。 四分。(29死亡; 2例诱导失败; 1例 雷塞塞德角发生第二次恶性肿瘤，1例患者。谁制定了 在CR时患有多形性胶质母细胞瘤，死于脑瘤。 较大 PT.要得出结论，就必须有更多的数字和更长的后续行动。

This trial was designed to improve the long-term survival of pts. with AIL. The study has evolved from an observation made within the NIH (NCI and NIAID) that pts. with Grade III AIL (or angiocentric lymphoma), who were treated with aggressive combination chemotherapy had a higher response rate and improved survival compared to pts. with Grades I or II AIL treated with low-dose alkylating agents and/or prednisone. Half of the pts. on low-dose chronic therapy eventually developed lymphomas refractory to treatment and most eventually succumbed to their disease. Thus pts. initially diagnosed with overt lymphoma enjoyed a greater long-term survival than pts. with diseases (grades I and II AIL) traditionally felt to be premalignant or benign inflammatory conditions. This study is intended to determine if all pts. with AIL will benefit from initial intensive combination chemotherapy. 14 pts. have been entered on study. 11 of 14 pts. (79%) have achieved a complete remission. 3 pts. have relapsed (27%); 2 of the 3 relapsers have undergone ABMT and are in durable 2nd remissions. One induction failure received radiation and is in durable remission. Four pts. (29%) have died; 2 induction failures; 1 relapsed pt. who developed a second malignancy and 1 pt. who developed a glioblastoma multiforme while in CR and died from his brain tumor. Larger pt. numbers and longer follow-up are necessary to draw from conclusions.